Clever Culture Systems Limited (ASX:CC5)

Market Cap	56.95M
Revenue (ttm)	3.37M
Net Income (ttm)	-799.00K
Shares Out	1.78B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,416,639
Average Volume	3,457,273
Open	0.0320
Previous Close	0.0320
Day's Range	0.0310 - 0.0330
52-Week Range	0.0120 - 0.0325
Beta	1.55
RSI	67.41
Earnings Date	Aug 22, 2025

About Ligand Pharmaceuticals

Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for medical industry in Australia, the United States, Sweden, the United Kingdom, and Germany. The company offers Automated Plate Assessment System (APAS) Independence, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; APAS Analysis Modules, a software algorithm that enables the screening of microbiology...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2004
• Employees: 19
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CC5

Financial Performance

In 2024, Clever Culture Systems's revenue was 1.26 million, a decrease of -41.09% compared to the previous year's 2.13 million. Losses were -3.74 million, -83.40% less than in 2023.